<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077634</url>
  </required_header>
  <id_info>
    <org_study_id>SPARE-001</org_study_id>
    <secondary_id>AUO study number</secondary_id>
    <nct_id>NCT02077634</nct_id>
  </id_info>
  <brief_title>Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)</brief_title>
  <acronym>SPARE</acronym>
  <official_title>Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory Phase 2 multicenter, randomized, open-label study with a randomization&#xD;
      allocation ratio of 1:1 [abiraterone acetate + prednisone + LHRH-therapy (Arm A) versus&#xD;
      abiraterone acetate + prednisone (Arm B)]. For both groups patients will receive a dose of&#xD;
      1000 mg abiraterone acetate and 10mg prednisone daily (QD). Study drug will be administered&#xD;
      as 4 x 250-mg abiraterone acetate tablets and prednisone will be administered as 5 mg orally&#xD;
      twice a day (BID). Patients randomized to the LHRH-therapy group will receive the same&#xD;
      LHRH-therapy they received prior to entering the trial. 70 medically castrated male patients&#xD;
      with metastatic CRPC who have shown tumor progression and are non- or mildly-symptomatic will&#xD;
      be enrolled from approximately 12 German study sites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radiographic-progression-free survival</measure>
    <time_frame>12 month</time_frame>
    <description>The primary objective of the study is to analyze the clinical benefit of abiraterone acetate plus prednisone while sparing LHRH-therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of radiographic-progression-free survival with early PSA-response</measure>
    <time_frame>12 month</time_frame>
    <description>To establish additional clinically relevant information regarding early PSA responses to abiraterone and to correlate these with radiographic-progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal analyses</measure>
    <time_frame>12 month</time_frame>
    <description>To investigate effects of both treatment arms on hormones of the pituitary gonadal axis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 month</time_frame>
    <description>To characterize the safety profile of abiraterone acetate while sparing LHRH-therapy in comparison to continuing LHRH-therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>abiraterone acetate + prednisone + LHRH-therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will continue their LHRH-therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>abiraterone acetate + prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will stop LHRH-therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate + prednisone + LHRH-therapy</intervention_name>
    <description>Hormon therapy will go on</description>
    <arm_group_label>abiraterone acetate + prednisone + LHRH-therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate + prednisone</intervention_name>
    <description>ormon therapy will be stopped</description>
    <arm_group_label>abiraterone acetate + prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent&#xD;
&#xD;
          2. Written Data Protection Consent has been obtained&#xD;
&#xD;
          3. Male aged 18 years and above&#xD;
&#xD;
          4. Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          5. Metastatic disease documented by positive CT/MRI and/or bone scan (both must be&#xD;
             performed). If lymph node metastasis is the only evidence of metastasis, it must be ≥2&#xD;
             cm in diameter&#xD;
&#xD;
          6. Prostate cancer progression documented by PSA according to PCWG2 or radiographic&#xD;
             progression according to modified RECIST criteria&#xD;
&#xD;
          7. Asymptomatic or mildly symptomatic from prostate cancer. A score of 0-1 for the&#xD;
             question of worst pain within last 24 hours (Appendix 8) will be considered&#xD;
             asymptomatic, and a score of 2-3 will be considered mildly symptomatic.&#xD;
&#xD;
          8. Medically castrated, with testosterone levels of &lt;20-50 ng/dl (&lt; 2.0 nM).&#xD;
&#xD;
          9. Combined androgen blockade is permitted, but not required. If patients received&#xD;
             combined androgen blockade with an anti-androgen they must have shown PSA progression&#xD;
             after discontinuing the anti-androgen prior to enrollment (≥4 weeks since last&#xD;
             flutamide, ≥6 weeks since last bicalutamide or nilutamide).&#xD;
&#xD;
         10. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2 (Appendix 6)&#xD;
&#xD;
         11. Hemoglobin ≥9.0 g/dL independent of transfusion&#xD;
&#xD;
         12. Platelet count ≥100,000 /μl&#xD;
&#xD;
         13. Serum albumin ≥3.0 g/dl&#xD;
&#xD;
         14. Serum creatinine &lt; 1.5 x ULN or a calculated creatinine clearance ≥60 ml/min (Appendix&#xD;
             7)&#xD;
&#xD;
         15. Serum potassium ≥3.5 mmol/l&#xD;
&#xD;
         16. Liver function:&#xD;
&#xD;
               1. Serum bilirubin &lt;1.5 x ULN (except for patients with documented Gilbert's&#xD;
                  disease)&#xD;
&#xD;
               2. AST or ALT &lt;2.5 x ULN&#xD;
&#xD;
         17. Able to swallow the study drug whole as a tablet&#xD;
&#xD;
         18. Life expectancy of at least 6 months&#xD;
&#xD;
         19. Patients who have partners of childbearing potential must be willing to use a method&#xD;
             of birth control with adequate barrier protection as determined to be acceptable by&#xD;
             the principal investigator and sponsor during the study and for 1 week after last&#xD;
             study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Surgical castration (i.e. orchiectomy).&#xD;
&#xD;
          2. Application of any LHRH-therapy (LHRH-analogue or LHRH-antagonist) within 3 months&#xD;
             (for patients receiving a 3-months formulation) or 1 months (for patients receiving a&#xD;
             1-month formulation) prior to Cycle 1 day 1.&#xD;
&#xD;
          3. Patients receiving a 6- or 12-months formulation of LHRH-therapy&#xD;
&#xD;
          4. Active infection or other medical condition that would make prednisone/prednisolone&#xD;
             (corticosteroid) use contraindicated&#xD;
&#xD;
          5. Any chronic medical condition requiring a higher dose of corticosteroid than 5mg&#xD;
             prednisone/prednisolone bid.&#xD;
&#xD;
          6. Pathological finding consistent with small cell carcinoma of the prostate&#xD;
&#xD;
          7. Liver or visceral organ metastasis&#xD;
&#xD;
          8. Known brain metastasis&#xD;
&#xD;
          9. Use of opiate analgesics for cancer-related pain, including codeine, tramadol, tilidin&#xD;
             and others (see Appendix 9), currently or anytime within 4 weeks of Cycle 1 Day 1.&#xD;
&#xD;
         10. Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC&#xD;
&#xD;
         11. Radiation therapy for treatment of the primary tumour within 6 weeks of Cycle 1, Day 1&#xD;
&#xD;
         12. Radiation or radionuclide therapy for treatment of metastatic CRPC&#xD;
&#xD;
         13. Prior treatment with Abiraterone acetate or other CYP17 inhibitors (ketoconazole,&#xD;
             TAK700, TOK001) ), Enzalutamide (Xtandi) or investigational agents targeting the&#xD;
             androgen receptor for prostate cancer for more than 7 days&#xD;
&#xD;
         14. Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4&#xD;
             weeks of Cycle 1, Day 1&#xD;
&#xD;
         15. Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1 (patients whose&#xD;
             PSA did not decline for three or more months in response to antiandrogen given as a&#xD;
             second line or later intervention will require only a two week washout prior to Cycle&#xD;
             1, Day 1)&#xD;
&#xD;
         16. Bicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of Cycle 1 Day 1&#xD;
             (patients whose PSA did not decline for three or more months in response to&#xD;
             antiandrogen given as a second line or later intervention will require only a two week&#xD;
             washout prior to Cycle 1, Day1)&#xD;
&#xD;
         17. Uncontrolled hypertension (systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg). Patients&#xD;
             with a history of hypertension are allowed provided that blood pressure is controlled&#xD;
             by anti- hypertensive treatment&#xD;
&#xD;
         18. Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
         19. History of pituitary or adrenal dysfunction&#xD;
&#xD;
         20. Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt;50 % at baseline&#xD;
&#xD;
         21. Any condition that requires treatment with Digoxin, digitoxin, and other digitalis&#xD;
             drugs&#xD;
&#xD;
         22. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy&#xD;
&#xD;
         23. Other malignancy with a ≥30 % probability of recurrence within 24 months, except non-&#xD;
             melanoma skin cancer.&#xD;
&#xD;
         24. Administration of an investigational therapy within 30 days of Cycle 1, Day 1&#xD;
&#xD;
         25. Any condition, which, in the opinion of the investigator, would preclude participation&#xD;
             in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten-Henning Ohlmann, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Onkologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie Bonn-Rhein-Sieg, Praxis Bad Godesberg</name>
      <address>
        <city>Bonn</city>
        <zip>53177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft für Urologie</name>
      <address>
        <city>Borken</city>
        <zip>46325</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22399</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Homburg/Saar, Klinik für Urologie und Kinderurologie</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Kempen</city>
        <zip>47906</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztpraxis Dr. Klier, Cologne-Study-Group</name>
      <address>
        <city>Köln</city>
        <zip>50968</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologisches Zentrum Lübeck (UZL)</name>
      <address>
        <city>Lübeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis PUR-R</name>
      <address>
        <city>Mülheim/Ruhr</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Urologie Pasing</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatärztliche urologische Studienpraxis</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandamed - Übag</name>
      <address>
        <city>Remscheid</city>
        <zip>42853</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Onkologie und Urologie Rostock, Wissenschaftskontor Nord GmbH &amp; Co. KG</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft für Onkologie und Urologie</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DGU</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandamed - Übag</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Urologie</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Urologie</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

